Agenus starts Phase II study of genital herpes treatment; Anti-cocaine vaccine shows promising results in exploratory study;

@AlisonBFierce: U. of Texas at Austin researchers got $6.5M from Dept. of Defense to develop new vaccines for emerging health threats. More | Follow @AlisonBFierce

> Drugstores can give people flu shots, but what about other vaccines? Story

> Genticel announced positive data from a Phase I trial of ProCervix in women infected with high-risk HPV. News

> Sanofi Pasteur filed a Supplemental Biologics License Application with the FDA for a quadrivalent formulation of its Fluzone vaccine. Release

> BiondVax Pharmaceuticals passed an EU quality control audit and will look to develop an oral delivery of its universal flu vaccine. Release

> Agenus ($AGEN) started a Phase II study of its HerpV vaccine for the treatment of genital herpes. Release

And Finally... An anti-cocaine vaccine combined with Immunovaccine's DepoVax showed promising results in an exploratory study. Release

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.